SBRT for Oligo-residual NSCLC After Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors

This study is testing stereotactic body radiation therapy (SBRT) — a precise, high-dose radiation technique — for patients with stage IV non-small cell lung cancer who still have a small number of remaining tumor sites after responding to immunotherapy (PD-1/PD-L1 checkpoint inhibitors). **You may be eligible if...** - You are 18 years or older and in reasonably good health (ECOG PS 0–1) - You have confirmed stage IV NSCLC without EGFR, ALK, or ROS-1 driver mutations - You had a good response to PD-1/PD-L1 immunotherapy but have a few remaining tumor sites amenable to SBRT - Any brain metastases must be stable and not requiring steroids **You may NOT be eligible if...** - Your tumor has EGFR, ALK, or ROS-1 mutations - You did not respond well to immunotherapy - You have too many remaining tumor sites for SBRT Talk to your doctor to see if this trial is right for you.